Opinion|Videos|July 5, 2023
Achieving Durable Clinical Response with Targeted Treatment for Vitiligo
In this MEDcast episode, Dr Chovatiya and Dr Bunick delve into the advancements in targeted treatments for vitiligo, exploring their potential to provide long-term efficacy and durable clinical response.
Advertisement
Episodes in this series
0:53 Quality of life impact of vitiligo
2:55 Pathogenesis of vitiligo
5:08 Approaches to vitiligo treatment
8:30 Mechanism of JAK inhibitors
10:25 TRuE-V1 and TRuE-V2 studies for the JAK inhibitor ruxolitinib
14:15 Variation in repigmentation with vitiligo
17:20 Safety of topical ruxolitinib
21:00 Data from the long-term extension trial of ruxolitinib
25:75 Achieving meaningful treatment response in vitiligo
30:15 Investigational biomarkers and treatments for vitiligo
Advertisement
Related to this article
In this Q&A, Armand explains why eczema visits spike during wildfire smoke events and how allergic patients can protect themselves.
In this Q&A, Leon Kircik, MD, discusses challenging watch-and-wait for molluscum contagiosum with berdazimer gel, 10.3%, at LEADderm 2026.
In this feature, several leaders in the dermatology space were asked how far we have come and where the field is headed in precision medicine.
FDA accepts Cogent's bezuclastinib NDA for advanced systemic mastocytosis, backed by APEX trial data showing durable, high-rate responses.
New research links wildfire smoke to lasting respiratory decline and skin flares, months after exposure ends.
Ameluz is now the first FDA-approved photodynamic therapy for a skin cancer, expanding use to superficial basal cell carcinoma (sBCC) in adults.
Adam Friedman, MD, breaks down how to say no strategically in dermatology, from delaying an answer to sharing the decision with the requester.
Kristina Duffin, MD, dean of the Spencer Fox Eccles School of Medicine, discusses leadership, delegation, and coaching at LEADderm 2026.
Advertisement
Advertisement
Trending on HCPLive
1
Vicadrostat EASi-KIDNEY Trial Discontinued for Lack of Benefit in CKD
2
ASH Issues New Ferritin Thresholds for Iron Deficiency Diagnosis
3
Immediate Coronary Angiography Does Not Improve Survival Outcomes in Cardiac Arrest
4
Atacicept Cuts IgAN Progression Risk 76% in ORIGIN 3 Final Data
5